ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1422	National Cancer Institute	Html	en	Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood liver cancer.	unfavorable hepatoblastoma 0.444228 liver tumors 0.560678 recurrent hepatoblastoma 0.435695 pediatric hepatoblastoma 0.454465 ruptured hepatoblastoma 0.423384 metastatic hepatoblastoma 0.509586 probable hepatoblastoma 0.453029 Eur J Cancer 0.388707 international pediatric liver 0.386143 multiply relapsed hepatoblastoma 0.447121 children 0.485632 Hepatoblastoma clinical research 0.47139 standard-risk hepatoblastoma 0.42407 clinical trials 0.40571 apparently sporadic hepatoblastoma 0.4599 weight hepatoblastoma cases 0.474502 Hepatoblastoma state 0.437405 International Society 0.406829 PRETEXT group assignment 0.412995 pediatric liver 0.555337 small cell hepatoblastoma 0.447198 pediatric liver tumors 0.460989 childhood hepatoblastoma 0.480002 pediatric liver resection 0.388074 familial adenomatous polyposis 0.407751	et al. 0.704223 congenital hepatoblastoma 0.4367 unresectable hepatoblastoma cases 0.452922 surgical resection 0.477903 PUBMED Abstract 0.546371 Pediatr Blood Cancer 0.795718 paediatric hepatoblastoma 0.439301 pediatric liver tumor 0.53573 advanced hepatoblastoma 0.46193 childhood liver cancer 0.393775 Liver Tumor Study 0.447606 newly diagnosed hepatoblastoma 0.454459 Pediatr Surg 0.416351 Abstract 0.708564 Pediatr Hematol Oncol 0.541505 Clin Oncol 0.519738 unresectable hepatoblastoma 0.472209 complete surgical resection 0.406131 hepatoblastoma 0.939626 high-risk hepatoblastoma 0.561704 childhood high-risk hepatoblastoma 0.538739 Oncology Liver Tumor 0.378181 hepatoblastoma patients 0.439703 Oncology Group 0.393362	CLICK HERE
1703	National Cancer Institute	Html	en	Tumor Grade	A fact sheet that discusses tumor grade and its role in prognosis. Explains concepts like normal cell biology and cell differentiation.	Gleason score 0.401724 NCI fact sheet 0.404685 lower grade 0.405507 tissue organization 0.400496 better prognosis 0.354968 tumor tissue 0.703634 type-specific grading systems 0.412132 tumor type 0.491464 cancer cells 0.405656 biopsied tissue 0.413701 Gleason scores 0.355221 primary brain tumors 0.42294 tumor size 0.501863 abnormal-looking cells 0.400459 Nottingham grading 0.360235 higher-grade cancer 0.364598 tumor cells 0.631844 normal cells 0.49423 nearby lymph nodes 0.408457 tumor grade 0.785451 regional lymph node 0.409603 secondary pattern 0.388809 breast tumors 0.384185 Scarff-Bloom-Richardson grading 0.361738	normal tissue structures 0.487646 primary pattern 0.353415 microscopic examination 0.353649 breast cancer 0.39308 biopsy samples 0.354483 Staging page 0.357155 microscopic appearance 0.359178 different types 0.358151 tumors 0.490957 prostate cancer 0.440387 cancer staging 0.368981 slower rate 0.360886 American Joint Committee 0.39399 tumor 0.981653 tumor grades 0.501473 common tissue pattern 0.44497 cancer 0.557882 total score 0.354108 soft tissue sarcoma 0.443518 prostate cancers 0.367392 Gleason scoring 0.35738 tumor tissue look 0.635152 cancer stage 0.457333	CLICK HERE
1737	National Cancer Institute	Html	en	Lasers in Cancer Treatment	A fact sheet that describes use of high-intensity light in cancer treatment, its advantages and disadvantages, and types of procedures that use it.	cancer treatment 0.596049 flexible endoscope 0.380536 health care provider 0.409067 body 0.411001 argon lasers 0.532774 high-intensity light 0.445412 clinical trials 0.451803 bright indoor light 0.427495 LITT 0.389656 Laser-induced interstitial thermotherapy 0.422778 seal lymph vessels 0.416005 specific wavelength 0.3683 lower risk 0.371973 laser light 0.694799 normal tissue 0.366241 clinical trials page 0.408776 Ordinary light 0.384552 radiation therapy 0.382841 powerful beam 0.363945 NCI fact sheet 0.529266 light bulb 0.385224 sheet Photodynamic Therapy 0.436155 standard surgical tools 0.542942 photodynamic therapy 0.436739 early stages 0.365543	optical fibers 0.421684 fact sheet Hyperthermia 0.42197 cancer cells 0.463993 colon polyps 0.373762 cell skin cancer 0.441978 Cancer Information Service 0.427676 interstitial laser photocoagulation 0.453094 lasers 0.686527 strict safety precautions 0.41161 precancerous growths 0.534102 light amplification 0.39079 laser surgery 0.440343 patient 0.366006 tumor cells 0.428295 PDT 0.367707 nerve endings 0.364934 precise surgical work 0.423122 superficial cancers 0.447776 YAG laser light 0.46252 laser therapy 0.900564 tumors 0.382431 cell lung cancer 0.440229 tiny areas 0.365703 narrow beam 0.364464	CLICK HERE
1806	National Cancer Institute	Html	es	Tratamiento del cáncer de estómago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago.	after d2 gastrectomy 0.313513 gastrectomía d2 0.31496 Cunningham D 0.34388 Macdonald JS 0.318723 Chemoradiotherapy after surgery 0.344328 randomised controlled 0.319618 combined modality therapy 0.360634 mejoría significativa 0.31176 Stenning SP 0.310838 intergroup trial calgb 0.31542 Postoperative adjuvant chemoradiation 0.322032 after ci 5-fu 0.317294 fase iii 0.364462 Estados Unidos 0.347269 with s-1 0.314235 randomized trial comparing 0.314288 quimiorradioterapia posoperatoria 0.360835 ensayo rtog-9904 0.324678 patients with 0.484752 adyuvante versus tasa 0.360686 supportive care 0.325372 Clinical Oncology 0.311085 Perioperative chemotherapy versus 0.334581 chemotherapy plus best 0.312401 Smalley SR 0.318682	with surgery 0.339493 Ajani JA 0.354002 or gastroesophageal junction 0.340588 ensayo swog-s0425 0.324881 Allum WH 0.311046 quimiorradioterapia adyuvante versus 0.364135 estadio ib 0.338006 gastrectomía curativa d2 0.319296 Van Cutsem E 0.313883 Benedetti J 0.318647 quimioterapia perioperatoria 0.352185 gastric carcinoma 0.325701 gastric cancer 0.935626 Clin Oncol 0.612714 or gastro-oesophageal junction 0.317111 trial comparing 0.314461 supportive care with 0.324232 Winter K 0.319459 Gastric Cancer Study 0.317632 chemotherapy versus surgery 0.338116 grupo s-1 0.317965 Okawara GS 0.319919 care with best 0.314996 quimioterapia posoperatoria 0.31518	CLICK HERE
1943	National Cancer Institute	Html	es	Síndromes cardiopulmonares (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el tórax. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, el derrame pleural maligno, el derrame pericárdico y el síndrome de la vena cava superior.	pleural catheter 0.17861 Ripamonti C 0.130559 dificultad respiratoria 0.26023 malignant effusion 0.115362 lung cancer 0.190962 Sin embargo 0.114284 end-of-life patients with 0.119385 indwelling pleural catheter 0.162022 Dudgeon DJ 0.13043 fármacos pleurales esclerosantes 0.112004 disfunción muscular respiratoria 0.121219 Hematol Oncol Clin 0.143013 hypoxemic patients with 0.118489 patients receiving chemotherapy 0.111162 Cancer Organisation Thoracic 0.117844 antitusivos opioides 0.112496 recurrent symptomatic malignant 0.110714 patients with 0.625852 insuficiencia cardiaca 0.134239 Pain Symptom Manage 0.478956 randomized controlled 0.112081 pleural fluid 0.136904 Cancer Dyspnea Scale 0.146703 Moroni M 0.110841 Care Cancer 0.128094	pleural catheter vs 0.135869 Physiol Neurobiol 0.116436 as symptomatic treatment 0.110943 derrame maligno fracasa 0.114534 obstructiva crónica 0.135859 vías respiratorias 0.205286 tunnelled pleural catheter 0.139919 tos crónica causa 0.111919 prospective randomized 0.110614 pleural effusions with 0.149859 Intern Med 0.132242 Clin Oncol 0.11762 Med Pediatr Oncol 0.111608 Clin North Am 0.136363 Bruera E 0.203018 systematic review 0.116364 Oncol Clin North 0.140711 American Thoracic Society 0.114142 as palliative treatment 0.110799 malignant pleural effusions 0.900896 Crit Care Med 0.171232 symptomatic malignant 0.122652 alone versus 0.11566 compared with 0.110951	CLICK HERE
1992	National Cancer Institute	Html	es	Tratamiento del tumor teratoideo/rabdoide atípico del sistema nervioso central infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores teratoideos/rabdoides atípicos del sistema nervioso central infantil.	tumores smarcb1 0.603767 células madre 0.629225 efectos secundarios meses 0.607017 siguientes aspectos 0.601615 siguientes especialistas 0.601426 genes smarcb1 0.609598 PDQ Descripción 0.60415 efectos tardíos 0.611777 PDQ Tumores 0.606157 PDQ Efectos tardíos 0.604371 National Cancer Institute 0.601403 siguientes riesgos 0.600917 profesional entrenado 0.601618 Instituto Nacional 0.6024 PDQ Tratamiento 0.603883	presente sumario 0.602507 determinados cambios 0.601063 presente sección 0.601013 nuevos tipos 0.601364 sistema nervioso central 0.98418 Physician Data Query 0.604988 brain tumor 0.602951 Aboutâ„¢ Brain Tumors 0.601752 ensayos clínicos.Terapia 0.60282 siguientes terapias 0.601133 siguientes enlaces 0.601027 Brain Tumor Consortium 0.605055 panel derecho 0.601581 siguientes trastornos 0.601436	CLICK HERE
2051	National Cancer Institute	Html	es	Vacunas contra el cáncer	Hoja informativa que define los tipos de vacunas y explica cómo funcionan, cómo se preparan, y describe la investigación relacionada con su uso.	stemness-related tumor 0.305626 Mortality Weekly Report 0.305127 cancer vaccines 0.384507 células t 0.36244 células apc 0.361199 immune system 0.308685 proteína llamada factor 0.306202 vacunas protegen 0.338385 promising treatment modality 0.305201 beyond current paradigms 0.30561 hepatitis b 0.31173 Estados Unidos 0.331683 Expert Opinion 0.310074 fuerte respuesta 0.312982 Sipuleucel-T immunotherapy 0.305397 PubMed Abstract 0.971511 fuertes respuestas 0.305062 tumor antigen discovery 0.307826 proteína llamada 0.309122 vacunas autólogas 0.332195 invasores foráneos 0.325813 papiloma humano tipos 0.309997 Therapeutic vaccines as 0.30821 British Medical Journal 0.305786 therapy through immunomodulation 0.306217	frecuencia citocinas 0.305145 Schlom J 0.308012 suficientes antígenos 0.322846 factor estimulador 0.309823 programmed cell death 0.30504 inmunitario llamadas células 0.349485 moving beyond current 0.316247 comprehensive immunization strategy 0.30562 vacunas alogénicas 0.333841 cabo respuestas 0.305615 Reviews Cancer 0.310845 Mutant MHC class 0.305006 TRICOM vector based 0.304939 stable metastatic breast 0.304849 Current Pharmaceutical Design 0.305726 Therapeutic Advances 0.304747 cuello uterino 0.354099 mutational neoepitopes reveals 0.305636 tumor model 0.304956 Clinical Cancer Research 0.341107 Gulley JL 0.308772 vacunas resultantes 0.336516 New England Journal 0.315061 células renales 0.33154	CLICK HERE
2082	National Cancer Institute	Html	en	Cancer Clusters	A fact sheet that describes what constitutes a cancer cluster and the process for reporting and investigating suspected clusters.	major risk factor 0.385962 specific environmental hazards 0.38074 rare cancer 0.409989 website uses data 0.380594 cancer trends 0.398646 individual cancer clusters 0.469731 number 0.405815 investigators 0.393508 Health Hazard Evaluation 0.380995 Disease Control 0.519415 Health Consultations page 0.381331 cancer cluster 0.895701 cancer clusters 0.841764 National Center 0.381056 ATSDR regional offices 0.380684 different geographic area 0.38274 cluster investigations 0.411002 true cancer clusters 0.482566 public health assessments 0.472612 statistically significant difference 0.384068 vinyl chloride 0.380035 specific cancer type 0.434002 primary cancer 0.413707 U.S. Census Bureau 0.37492 specific hazardous substances 0.37613	different cancer types 0.429181 state health department 0.450442 total number 0.385248 cancer cases 0.749447 health departments 0.457783 NCI analyze variations 0.380726 local health departments 0.450682 geographic area 0.518161 specific geographic area 0.389344 health surveillance programs 0.382617 people 0.378106 epidemiologic study 0.378396 agency gathers information 0.381997 statistically significant excess 0.455543 secondary cancer 0.393665 cancer 0.954313 state cancer registries 0.443891 cancer cluster—that 0.391887 Disease Registry 0.381886 specific time period 0.392616 Toxic Substances 0.380998 cancer death rates 0.436653 cancer incidence 0.401099 Cancer Mortality Maps 0.435229	CLICK HERE
16162	National Cancer Institute	Html	en	New Therapies Are Changing the Outlook for Advanced Melanoma	An article about a host of new treatment options that have been produced in the last several years for patients with the skin cancer melanoma.	improved progression-free survival 0.366558 new therapies 0.351845 target BRAF proteins 0.357172 commonly used therapies 0.342946 BRAF inhibitor 0.43187 BRAF mutations 0.802264 Cancer Therapy Evaluation 0.357896 Overall survival results 0.381093 Dr. Schuchter 0.658164 overall survival 0.53856 clinical trials 0.561097 results 0.412771 median progression-free survival 0.364224 clinical trial 0.629151 median overall survival 0.359384 patients 0.941423 recent FDA-approved drugs 0.349384 tumor responses 0.376799 metastatic melanoma 0.378989 chemotherapy drug dacarbazine 0.34213 median survival 0.400006 melanoma specialist 0.389264 large clinical trial 0.469476 MEK inhibitor 0.413513	cancer cells 0.348742 Patient tumor samples 0.353483 skin-related side effects 0.386676 MEK inhibitor cobimetinib 0.40543 clinical trial participants 0.357541 BRAF-MEK inhibitor combination 0.3755 Dr. Streicher 0.487979 tumor cells 0.429743 checkpoint inhibitor 0.371337 small clinical trials 0.342687 drugs 0.41439 progression-free survival 0.707667 MEK inhibitors 0.605005 advanced melanoma 0.87481 PD-1 inhibitor 0.342866 recent clinical trials 0.345485 new treatment options 0.457424 tumors 0.426135 New Melanoma Therapies 0.48664 early-phase clinical trial 0.367414 Moffitt Cancer Center 0.358773 regulatory approval 0.407964 Pennsylvania Abramson Cancer 0.343564 skin cancer melanoma 0.49678	CLICK HERE
17279	National Cancer Institute	Html	es	Planes para atender un cáncer avanzado	Una planificación cuidadosa reducirá el peso que enfrentará su familia más adelante. La planificación puede incluir aspectos económicos y legales, pero como verá, también puede ser una forma de celebrar su vida y de darle significado.	tensiones. Algunas personas 0.876955		CLICK HERE